• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Email - Information Request, May 31, 2011 - HPC Cord Blood

 

From:   Sista, Ramani V
Sent:     Tuesday, May 31, 2011 12:42 PM
To:       'Miller, Sharon'
Subject:            BLA 125391 - Information Request-1
 
Importance:      High
Hi Sharon,
We look forward to speaking with you later today. Please see below for information requested by the Clinical reviewer:
 
 
1.         Please provide the following information or identify where the following information located in the submission:
 
a.         This product may be subject to the Pediatric Research Equity Act and if the data to support intended indications do not cover all pediatric age groups (including neonates), you need to include in your submission a request for a waiver or deferral of the pediatric assessment.
b.         Copy of data set used for your safety outcome analysis. The data set must be submitted as a SAS transport file.
c.         SOP for elicitation and handling of post donation information
d.         SOP for elicitation and handling of recipient adverse events
e.         SOP for notification of mothers or their responsible physicians of positive or indeterminate test results according to local or national regulations
f.          Validation of physician training materials
g.         Please clarify if B5.100.4 is your plan for assessment of clinical outcome data in the post marketing period
 
Thanks,
Ramani
 
 
Ramani Sista, PhD, RAC
Regulatory Project Manager
Office of Cellular Tissue & Gene Therapies
CBER, FDA
Phone: 301-827-5152
Fax: 301-827-9796
Ramani.Sista@fda.hhs.gov
 
THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.